
Sign up to save your podcasts
Or


Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
By STAT4.5
309309 ratings
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.

30,734 Listeners

1,942 Listeners

493 Listeners

9,536 Listeners

6,074 Listeners

390 Listeners

62 Listeners

86 Listeners

33 Listeners

523 Listeners

5,510 Listeners

20 Listeners

51 Listeners

392 Listeners

12 Listeners